Celldex

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Celldex and other ETFs, options, and stocks.

About CLDX

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases.

CEO

Anthony S. Marucci

CEOAnthony S. Marucci

Employees

186

Employees186

Headquarters

Hampton, New Jersey

HeadquartersHampton, New Jersey

Founded

1983

Founded1983

Employees

186

Employees186

CLDX Key Statistics

Market cap

1.78B

Market cap1.78B

Price-Earnings ratio

-8.92

Price-Earnings ratio-8.92

Dividend yield

—

Dividend yield—

Average volume

915.50K

Average volume915.50K

High today

$27.01

High today$27.01

Low today

$26.03

Low today$26.03

Open price

$26.35

Open price$26.35

Volume

688.29K

Volume688.29K

52 Week high

$29.38

52 Week high$29.38

52 Week low

$14.40

52 Week low$14.40

CLDX News

Simply Wall St 3d

Celldex Therapeutics: Assessing Valuation as Barzolvolimab Hype and Biotech Optimism Drive Renewed Investor Focus

Celldex Therapeutics (CLDX) has seen renewed interest as excitement builds over barzolvolimab's outlook in chronic urticaria, along with broader positive moment...

TipRanks 6d

Celldex initiated with an Underweight at Barclays

Barclays initiated coverage of Celldex (CLDX) with an Underweight rating and $25 price target The firm launched coverage of eight companies across inflammation...

Analyst ratings

80%

of 15 ratings

Buy

80%

Hold

13.3%

Sell

6.7%

People also own

Based on the portfolios of people who own CLDX. This list is generated using Robinhood data, and it’s not a recommendation.